• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Brief: Hepatitis C/AASLD 2010 Product Image

Brief: Hepatitis C/AASLD 2010

  • Published: December 2010
  • 23 Pages
  • Datamonitor

Data from Phase III studies for Vertex/Johnson & Johnsons telaprevir and Merck & Cos boceprevir were the main focus at the AASLD meeting in November 2010. Since both drugs are likely to be approved at the same time, comparisons of their respective Phase III data, and likely usage in different patient populations, dominated the discussion

Scope

- In-depth discussion of pivotal Phase III data for telaprevir and boceprevir in treatment-nave and treatment-experienced patients

- Analysis of the data presented from various key interferon-sparing studies.

Highlights

Safety and efficacy data from various trials assessing the use of interferon-sparing regimens suggest that interferon-sparing regimens are feasible. However, a greater insight into issues such as resistance is required in order to progress towards combination therapy with oral small molecule antivirals alone.

Reasons to Purchase

- Comparison and discussion of the data presented for the three most advanced HCV protease inhibitors at AASLD 2010

- Gain insight into the issues concerning the use of interferon-sparing regimens and the feasibility of such approaches

KEY FINDINGS

- The high unmet need for improved drugs in hepatitis C therapy has led to a highly active pipeline
- ADVANCE and ILLUMINATE data indicate that telaprevir can cut treatment duration in half in treatment-naive patients
- ADVANCE results confirm telaprevirs efficacy in treatment-naive patients
- Results from the ILLUMINATE study demonstrate that duration of therapy can be cut to 24 weeks in two thirds of treatment-naive genotype 1 patients
- Top-line data from REALIZE study show improved efficacy rates in treatment-experienced patients receiving telaprevir
- SPRINT-2 and RESPOND-2 results confirm boceprevirs efficacy in treatment-naive and experienced patients
- SPRINT-2 results demonstrate boceprevirs efficacy in treatment-naive patients
- RESPOND-2 data confirm boceprevirs efficacy in treatment-experienced patients
- Telaprevir and boceprevir will compete head to head after their expected launch in
- TMC435 demonstrates impressive efficacy in treatment-naive and -experienced patients
- Results from the study investigating the combination of BMS-790052 and BMS-650032 (Bristol-Myers Squibb) suggest resistance will be a key hurdle for interferon-sparing regimens
- Data from the study investigating the combination of BI 201335 and BI 207127 (Boehringer Ingelheim) indicates early antiviral activity
- A paradigm shift in HCV therapy is unlikely to occur in the short- to mid-term future

BIBLIOGRAPHY
- Literature

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos